ADMA Biologics Inc (NASDAQ:ADMA) Shares Acquired by Public Sector Pension Investment Board

Key Points

• The Public Sector Pension Investment Board increased its holdings in ADMA Biologics by 27.3% during the first quarter, acquiring a total of 749,702 shares valued at approximately $14.87 million.
• Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics, resulting in a 2.05% decrease in his ownership, while insider selling has totaled 464,621 shares over the last 90 days.
• ADMA Biologics reported earnings of $0.15 per share for the last quarter, exceeding analysts' expectations, with a revenue of $121.98 million marking a 13.8% year-over-year increase.

Public Sector Pension Investment Board boosted its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 27.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 749,702 shares of the biotechnology company's stock after purchasing an additional 160,762 shares during the period. Public Sector Pension Investment Board owned about 0.32% of ADMA Biologics worth $14,874,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of ADMA. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of ADMA Biologics during the first quarter valued at approximately $35,000. Tsfg LLC bought a new stake in shares of ADMA Biologics during the first quarter valued at approximately $51,000. Harvest Fund Management Co. Ltd bought a new stake in shares of ADMA Biologics during the first quarter valued at approximately $52,000. Farther Finance Advisors LLC boosted its position in shares of ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of ADMA Biologics during the fourth quarter valued at approximately $85,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on ADMA. Raymond James Financial boosted their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

Insider Buying and Selling at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,621 shares of company stock worth $9,644,269. 3.50% of the stock is currently owned by insiders.

ADMA Biologics Trading Up 0.1%

Shares of ADMA stock traded up $0.02 on Friday, reaching $16.99. 3,108,545 shares of the company's stock were exchanged, compared to its average volume of 3,154,640. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $4.06 billion, a PE ratio of 19.76 and a beta of 0.38. The company's fifty day simple moving average is $18.36 and its 200 day simple moving average is $18.83.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%. The firm had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same period last year, the company earned $0.13 EPS. ADMA Biologics's quarterly revenue was up 13.8% compared to the same quarter last year. As a group, analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.